Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 46

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 46
---
b) |    |     | Number of               
 securities remaining    
 available for future    
 issuance under equity   
 compensation plans      
 (excluding securities   
 reflected in column(a)) |       (c) |    |
|:-----------------------------------------------------------|:----|:------------------|-----------:|---:|:----|:------------|------:|---:|:----|:------------------------|----------:|---:|
| Equity compensation plans approved by security holders     |     |                   | 10,462,129 | -1 |     | $           | 13.43 | -2 |     |                         | 4,542,783 | -3 |
| Equity compensation plans not approved by security holders |     |                   |          — |    |     |             |     — |    |     |                         |         — |    |
| Total                                                      |     |                   | 10,462,129 |    |     | $           | 13.43 |    |     |                         | 4,542,783 |    |

| (1) | Includes 8,897,489 shares of Common Stock that were subject to outstanding option awards as of December 31, 2024 under the 2021 Plan and 1,564,640 shares of Common Stock that were subject to outstanding option awards as of December 31, 2024 under the 2020 Plan. |

| (2) | Represents the weighted-average exercise price of outstanding options. |

| (3) | Includes 3,051,588 shares of Common Stock available for issuance under the 2021 Plan and 1,491,195 shares of Common Stock available for issuance under the 2021 ESPP (all of which were eligible for purchase pursuant to the offering period in effect on December 31, 2024). This amount does not include any additional shares that may become available for future issuance under the 2021 Plan pursuant to the automatic increase to the share reserve on January 1 of each of our calendar years beginning 2025 and continuing through 2031 by the number of shares equal to the lesser of (i) 5% of the total outstanding shares of our Common Stock as of the immediately preceding December 31 and (ii) such smaller number of shares as is determined by our Board. Additionally, this amount does not include any additional shares that may become available for future issuance under the 2021 ESPP pursuant to the automatic increase to the share reserve on January 1 of each of